AFP and metabolic dysfunction-associated steatotic liver disease: The final Cox proportional hazards multivariable model showed no significant impact of NAFLD status on survival in patients receiving sorafenib (HR: 0.96, 95% CI: 0.79–1.17, p = 0.69) when adjusted for BCLC and CTP stage, tumour size  >7 cm, AFP > 400 IU/l, presence of cirrhosis, presence of extrahepatic metastases, dose, duration of therapy or receipt of previous therapy (Table 3).